TY - JOUR
T1 - Interferon-α acts on the S/G2/M phases to induce apoptosis in the G1 phase of an IFNAR2-expressing hepatocellular carcinoma cell line
AU - Maeda, Sakae
AU - Wada, Hiroshi
AU - Naito, Yoko
AU - Nagano, Hiroaki
AU - Simmons, Szandor
AU - Kagawa, Yoshinori
AU - Naito, Atsushi
AU - Kikuta, Junichi
AU - Ishii, Taeko
AU - Tomimaru, Yoshito
AU - Hama, Naoki
AU - Kawamoto, Koichi
AU - Kobayashi, Shogo
AU - Eguchi, Hidetoshi
AU - Umeshita, Koji
AU - Ishii, Hideshi
AU - Doki, Yuichiro
AU - Mori, Masaki
AU - Ishii, Masaru
PY - 2014
Y1 - 2014
N2 - Interferon-α (IFN-α) is used clinically to treat hepatocellular carcinoma (HCC), although the detailed therapeutic mechanisms remain elusive. In particular, IFN-α has long been implicated in control of the cell cycle, but its actual point of action has not been clarified. Here, using time lapse imaging analyses of the human HCC cell line HuH7 carrying a fluorescence ubiquitination- based cell cycle indicator (Fucci), we found that IFN-α induced cell cycle arrest in the G0/G1 phases, leading to apoptosis through an IFN-α type-2 receptor (IFNAR2)-dependent signaling pathway. Detailed analyses by time lapse imaging and biochemical assays demonstrated that the IFN-α/IFNAR2 axis sensitizes cells to apoptosis in the S/G2/M phases in preparation for cell death in the G 0/G1 phases. In summary, this study is the first to demonstrate the detailed mechanism of IFN-α as an anticancer drug, using Fucci-based time lapse imaging, which will be informative for treating HCC with IFN-α in clinical practice.
AB - Interferon-α (IFN-α) is used clinically to treat hepatocellular carcinoma (HCC), although the detailed therapeutic mechanisms remain elusive. In particular, IFN-α has long been implicated in control of the cell cycle, but its actual point of action has not been clarified. Here, using time lapse imaging analyses of the human HCC cell line HuH7 carrying a fluorescence ubiquitination- based cell cycle indicator (Fucci), we found that IFN-α induced cell cycle arrest in the G0/G1 phases, leading to apoptosis through an IFN-α type-2 receptor (IFNAR2)-dependent signaling pathway. Detailed analyses by time lapse imaging and biochemical assays demonstrated that the IFN-α/IFNAR2 axis sensitizes cells to apoptosis in the S/G2/M phases in preparation for cell death in the G 0/G1 phases. In summary, this study is the first to demonstrate the detailed mechanism of IFN-α as an anticancer drug, using Fucci-based time lapse imaging, which will be informative for treating HCC with IFN-α in clinical practice.
UR - http://www.scopus.com/inward/record.url?scp=84906569017&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84906569017&partnerID=8YFLogxK
U2 - 10.1074/jbc.M114.551879
DO - 10.1074/jbc.M114.551879
M3 - Article
C2 - 25012666
AN - SCOPUS:84906569017
SN - 0021-9258
VL - 289
SP - 23786
EP - 23795
JO - Journal of Biological Chemistry
JF - Journal of Biological Chemistry
IS - 34
ER -